Brightgene Bio-Medical Technology Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2001-10-26
- Employees
- 1.1K
- Market Cap
- -
- Website
- http://www.bright-gene.com
Clinical Trials
10
Active:0
Completed:4
Trial Phases
4 Phases
Phase 1:3
Phase 2:3
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (30.0%)Phase 2
3 (30.0%)Not Applicable
2 (20.0%)Phase 3
2 (20.0%)Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
Not Applicable
Recruiting
- Conditions
- Non-diabetic Overweight or Obese
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT07166081
- Locations
- 🇺🇸
Pharmaron CPC, Inc, Baltimore, Maryland, United States
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 477
- Registration Number
- NCT07064486
- Locations
- 🇮🇩
RS Universitas Indonesia, Depok, West Java, Indonesia
🇮🇩RSUP Fatmawati, Jakarta, Indonesia
🇮🇩RSUP Persahabatan, Jakarta, Indonesia
A Study of BGM0504 in Chinese Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: BGM0504 Administered SCDrug: Semaglutide Administered SCDrug: Placebo Administered SC
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT06974825
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06973681
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, China
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Overweight or Obese
- Interventions
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06929156
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital, Shandong Province), Jinan City, Shandong, China
- Prev
- 1
- 2
- Next
News
No news found